Research and Markets: 2007 Profile Provides an in-Depth Insight into the Dealmaking Activity and Interests of Amgen

Business Wire, Oct 5, 2007

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c70576) has announced the addition of Amgen Dealmaking Profile 2007 to their offering.

Each Company Dealmaking Profile provides an in-depth insight into the dealmaking activity and interests of one of the worlds leading biopharma companies.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives.

The initial chapters of each report provide an orientation of bigpharma's dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2006 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers in 2005 and 2006 in M&A and partnering deals announced, whilst chapter 4 identifies the top deals of 2005-6 according to reported deal size.

The main body of each report is provided in chapter 5. An in-depth profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company's marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. The profile also includes in-depth contact information for individuals within the business development function.

The company profile is also provided with a comprehensive listing of contract documents available in the public domain. The listing is sorted by deal type - therefore co-promotion deals are listed separately to licensing, M&A and supply deals, and so on.

Key benefits

Company Dealmaking Profiles provide the user with the following key benefits:

* Get ahead of your competitors by understanding and contacting the best partners of choice

* Identify prospective partner companies by analyzing their dealmaking activity and interests

* Undertake initial due diligence to assess suitability of partner companies

* Make direct contact with named business development executives within the company

* Review actual contract agreements entered into by the company and its partner companies

* Understand the key deal terms the company has agreed in previous deals

Report scope

Company Dealmaking Profiles are intended to provide business development executives, senior management and investors with decision-critical intelligence on a prospective partner's activities, interests and actual agreement contracts as signed by the company and its partners.

Each Company Dealmaking Profile includes:
- Company contact details - named contacts with their direct contact
  information
- Subsidiary companies
- Primary therapy areas
- Business development contacts
- Company description
- Marketed therapeutic indications
- Pipeline (phase I-III) therapeutic indications
- Partnering interests
- Partnering interests - therapeutic indications
- Partnering frequency per annum - 2000-2006
- Current partner companies (2005-6)
- Recent deals 2005-2006
By deal type
By stage of development
By therapy area
- Contract documents available online 2005-2006 - link direct to each
  document

Each contract document is accessible through a link to an online version of the actual contract document as filed with the Securities Exchange Commission. Analyzing actual company agreements allows assessment of the following:

- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner
  or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?

Each report is comprised of approx. 40 pages links to the online contract documents.

Content Outline:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Bigpharma - The Top 50

Chapter 3 - Most active bigpharma dealmakers
Bigpharma M&A activity
Bigpharma partnering

Chapter 4 - Top bigpharma deals - 2000-6
Bigpharma M&A Bigpharma partnering

Chapter 5 - Company Profile
How to use company profiles
Field definitions
Company profile
 Company contact details
 Subsidiary companies
 Primary therapy areas
 Business development contacts
 Company description
 Marketed therapeutic indications
 Pipeline (phase I-III) therapeutic indications
 Partnering interests
 Partnering interests - therapeutic indications
 Partnering frequency per annum - 2000-2006
 Current partner companies (2005-6)
 Recent deals 2005-2006
  By deal type
  By stage of development
  By therapy area
 Contract documents available online - link direct to each document

Chapter 6 - Resources

Order Form - Reports
Order Form - Company Dealmaking Profiles
Order Form - Report Update Subscription
Order Form - Contract Sets
Order Form - Contract Documents

Figures in report

Figure 1: Bigpharma - top 50 by pharma revenues 2006
Figure 2: Leading Bigpharma M&A companies, 2005-6
Figure 3: Leading Bigpharma partnering companies, 2005-6
Figure 4: Leading M&A deals by value, 2005-6
Figure 5: Leading partnering deals by value, 2005-6